Summary:
Immune checkpoint pathways have transformed modern immunology and cancer research, with PD‑1 signaling emerging as one of the most important regulators of T‑cell activity. Functional antibodies that modulate the PD‑1 pathway are essential tools for understanding immune regulation, restoring anti‑tumor responses, and evaluating next‑generation immunotherapies.
In this webinar, Dr. Gordon Freeman explores how PD‑1 blockade antibodies are used to interrogate immune checkpoint biology and model therapeutic mechanisms in preclinical systems. The session highlights experimental strategies for studying T‑cell exhaustion, checkpoint inhibition, and translational immuno‑oncology using functional antibodies designed for in vivo performance.
Topics Covered:
How researchers use PD‑1 pathway antibodies to:
- Investigate T‑cell exhaustion and immune checkpoint signaling
- Model checkpoint blockade therapies in preclinical systems
- Study immune regulation in cancer and inflammatory disease models
- Translate mechanistic discoveries into immunotherapy strategies
Speaker:
Gordon Freeman, PhD
Professor, Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School